The new monitoring technology captures, consolidates and organizes clinical information in real-time from disparate sources using a centralized approach to risk-based monitoring. According to the company, drug developers can accurately identify study risks and rapidly determine what type of intervention may be required. The monitoring, focused on specific risk, aims to enhance patient safety, reduce costs and promote regulatory compliance.
“Perceptive MyTrials Data-Driven Monitoring uses clinical data to guide monitoring activities as an alternative to periodically scheduled monitoring visits, which can be time-consuming, costly and inefficient,” said Xavier Flinois, president of PAREXEL Informatics. “Greater insight into study data allows for a more precise determination of when on-site monitoring visits need to occur and what activities should be undertaken during those visits. This can make clinical trial participation safer for patients while offering cost efficiencies for sponsors.”